ABIONYX Pharma

Business and Financial Review • Feb 4, 2020

Press Release

Cash position and activity update for Q4 2019

Cash position of €8.3 million at 31 December 2019

Toulouse, FRANCE, Lakeland, UNITED-STATES, February 4, 2020, 8:30pm CET – ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announces today that cash and cash equivalents totaled €8.3 million at December 31, 2019.

The activities of ABIONYX Pharma are focused on the discovery and development of innovative therapies to improve the lives of patients; the company did not generate any revenues during 2019, as expected.

As announced previously, possible collaborations with external partners are under consideration, and the company reasserts its commitment to communicating a new strategic development plan by the end of the first quarter of 2020.

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy.

Contacts :

NewCap Investor relations Louis-Victor Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53

NewCap Media relations Nicolas Merigeau abionyx@newcap.eu +33 (0)1 44 71 94 98